Evidence map›Paper›PMID 19038459›Full record

ArticleMolecular immunology2009

Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Gayle M Boxx, Casey T Nishiya, Thomas R Kozel, Mason X Zhang

Open access · greenAbstract read
In one paragraph

Article in Molecular immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. The Fungal Cell Wall:Frontiers in microbiology · 2019
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gayle M BoxxDepartment of Biological Sciences, California State University, Long Beach, CA 90840, USA.
Casey T Nishiya
Thomas R Kozel
Mason X Zhang
California State University, Long Beach · USUniversity of Nevada, Reno · US

Funding

Yeast Endosome to Vacuole Mutants--Evaluation/CloningS06GM063119 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI KINGSFORD, LAURA · 2001 to 2008
$12.1M
PHOSPHOMANNOPROTEIN ADHESIN AS A VACCINE CANDIDATEP01AI037194 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI EDWARDS, JOHN E. · 1995 to 2003
$3.6M
Cryptococcal polysaccharide-phagocytosis inhibitionR01AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1985 to 2009
$1.9M
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITIONR37AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1995 to 2004
$1.5M
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANSR01AI044786 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 2000 to 2004
$1.2M
Isotype-dependent efficacy of human mAbs against CandidaR15AI052139 · NIAID · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI ZHANG, MASON X · 2002 to 2002
$143k
NIAID NIH HHS AI14209NIAID NIH HHS AI37194NIAID NIH HHS AI44786NIAID NIH HHS AI52139NIAID NIH HHS P01 AI037194NIAID NIH HHS R01 AI014209NIAID NIH HHS R01 AI044786NIAID NIH HHS R15 AI052139NIAID NIH HHS R37 AI014209NIGMS NIH HHS GM63119NIGMS NIH HHS S06 GM063119
6 · The paper itself

Abstract

The complement system has an important role in host resistance to systemic candidiasis but regulation of complement activation by Candida albicans remains poorly defined. Previous studies have identified a requirement for naturally occurring antimannan IgG antibody in initiation of C3 opsonization of C. albicans through either the classical or alternative pathway. This study characterized antibody-dependent initiation of the alternative pathway using the recombinant human monoclonal antimannan Fab fragment M1 and its full-length IgG1 antibody M1g1. Kinetic analysis of C3b deposition onto C. albicans with flow cytometry demonstrated the ability of M1g1 to restore the activity of either the classical or alternative pathway to the yeast-absorbed normal human serum, but the Fc-free M1 Fab restored only the activity of the alternative pathway. This Fc-independent, antimannan Fab-mediated C3 deposition through the alternative pathway was also observed in a serum-free assay containing the six alternative pathway proteins and in C1q- or C2-depleted serum but not in factor B-depleted serum. M1- or M1g1-dependent alternative pathway initiation of C3b deposition occurred in an asynchronous manner at discrete sites that expanded to cover the entire cell surface over time as revealed with immunofluorescence microscopy, in contrast to a uniform appearance of initial C3 deposition through the classical pathway. Furthermore, antimannan Fab M1 promoted the assembly of the alternative pathway convertase on the cell surface seen as colocalization of C3 and factor B with immunofluorescence microscopy. Thus, human antimannan antibody has a distinct Fc-independent effector function in regulation of C3 deposition to C. albicans.

Indexed as

AntibodiesCandida albicansComplement ActivationComplement C3Complement C3-C5 ConvertasesComplement Pathway, AlternativeComplement Pathway, ClassicalHumansImmunoglobulin Fab FragmentsImmunoglobulin GKineticsMannansReceptors, FcRecombinant ProteinsAntibodiesComplement C3Complement C3-C5 ConvertasesImmunoglobulin Fab FragmentsImmunoglobulin GMannansReceptors, FcRecombinant Proteins

Identifiers

PMID19038459
PMCPMC2670400
OpenAlexW2014653719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.